ADAR1 Capital Management, LLC is an investment firm that reports beneficial ownership of shares in TENAX THERAPEUTICS, INC. (TENX) and 4 other companies under U.S. securities law. It has submitted 11 SEC insider filings since 2025, most recently in September 2026.
Every role ADAR1 Capital Management, LLC has reported on a Form 4, reconstructed from the filings themselves. Reporting insiders must state their relationship to the issuer (officer title, director seat, or 10% ownership) on every filing.
InMed Pharmaceuticals Inc. (INM)2 filingsTENAX THERAPEUTICS, INC. (TENX)3 filingsNextCure, Inc. (NXTC)2 filingsLatest filing:
ADAR1 Capital Management, LLC is 10% Owner of InMed Pharmaceuticals Inc. (INM). 13 SEC Form 4 filings on record going back to 2025, most recently on 16 September 2026. Most recent open-market trade: bought $11K of INM on 16 September 2026. Lifetime open-market purchases: $11.58M. Lifetime open-market sales: $95.66M. Historical track record: 5/5 stars across 17 tracked purchases.
Every recent SEC Form 4 transaction ADAR1 Capital Management, LLC has reported, most recent first.
InsiderAlpha computes a forward-return-based score for every insider with enough Form 4 purchase history. The metrics below reflect realized performance after each tracked open-market purchase.
| Metric | Value |
|---|---|
| InsiderAlpha rating | ★★★★★ (5/5) |
| Total purchases tracked | 17 |
| Purchases with forward-return data | 17 |
| 30-day win rate | 82% |
| 90-day win rate | 82% |
| Avg 5-day return | +1.96% |
| Avg 30-day return | +9.28% |
| Avg 90-day return | +12.43% |
| Best 30-day return |
InsiderAlpha's records for ADAR1 Capital Management, LLC go back to 2025: 13 primary Form 4 filings, an average of 6.5 per year. The typical open-market purchase is $282K (41 buys totaling $11.58M). The largest single buy on record is $1.63M of RLYB in 2026. Sales side: 3 recorded sales totaling $95.66M, so the filing history runs sell-heavy by dollar value. No recorded transaction carries a Rule 10b5-1 plan flag. An absent flag does not establish whether a transaction was pre-arranged or discretionary.
Insiders who reported open-market trades in the last 12 months at the companies ADAR1 Capital Management, LLC files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:
ADAR1 Capital Management, LLC is an investment firm, tracked as 10% Owner of InMed Pharmaceuticals Inc. (INM). InsiderAlpha holds 13 primary Form 4 filings for it, the earliest from 2025, updated as new SEC EDGAR filings are processed.
7 primary Form 4 filings in the last 90 days, covering 3 companies.
Recorded transactions: 41 open-market purchases ($11.58M) and 3 open-market sales ($95.66M) across all tracked filings.
Across 17 tracked purchases, ADAR1 Capital Management, LLC averaged +9.3% avg 30-day return with a 82% 30-day win rate. InsiderAlpha rates the track record at 5/5 stars.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
A free account opens the full scored daily plan and every past day, a watchlist for any ticker, and 3 months of price history on every company page. No card.
Free plan available · Paid plans start with a 7-day free trial
$INM InMed Pharmaceuticals Inc.28.5K shares @ $1.29$37K
| +13.86% |